Manual of clinical dialysis

Manual of Clinical Dialysis

Volumn , Issue , 2009, Pages 1-245

  Ahmad, Suhail ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891478292     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-09651-3     Document Type: Book

References (210)

1. Ahmad S, Gallagher N, Shen F. Intermittent peritoneal dialysis: status reassessed. Trans Am Soc Artif Intern Organs 1979, 25:86-89.
2. Kim WG, Yoon CJ. Roller pump induced tubing wear of polyvinylchloride and silicone rubber tubing: phase contrast and scanning electron microscopic studies. Artif Organs 1998, 22:892-897.
3. ANSI/AAMI RD62:2006 with permission of the Association for the Advancement of Medical Instrumentation, Inc. (C) 2006 AAMI www.aami.org. All rights reserved.
4. Kossmann RJ, Gonzales A, Callan R, Ahmad S: Citrate Dialysate Decreases Aluminum Burden in Hemodialysis Patients. ASN abstract, 2008.
5. Ahmad S, Callan R, Cole J, Blagg C: Increased Dialyzer Reuse with Citrate Dialysate. Hemodial Int 9:264-267, 2005.
6. Janssen MJ, Deegens JK, Kapinga TH et al. Citrate compared to low molecular weight heparin in chronic hemodialysis patients. Kidney Int 1996, 49:806-813.
7. Pinnick E, Wiegmann TE, Diederich DA. Regional anticoagulation for hemodialysis in the patients at high risk for bleeding. N Engl J Med 1983, 308:258-261.
8. VonBrecht JH, Flanigan MJ, Freeman RM et al. Regional anticoagulation-hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986, 8:196-201.
9. Ahmad S, Callan R, Cole JJ et al. Dialysate made from dry chemical using citric acid increases dialysis dose. Am J Kidney Dis 35(3):493-499, 2000.
10. Anonymous. Clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kid Dis 1997, 30(Suppl 3):S154-S191.
11. Rubens F, Wellington JL. Brachiocephalic fistula: A useful alternative for vascular access in chronic hemodialysis. Cardiovasc Surg 1993, 1:128-130.
12. Schwab SJ, Raymond JR, Saeed M et al. Prevention of fistula thrombosis: Early detection of venous stenosis. Kidney Int 1989, 36:707-711.
13. Besarab A, Sullivan K, Ross R et al. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenosis prior to thrombosis. Kidney Int 1995, 47:1364-1673.
14. Besarab A, Frinak S, Aslam M: Pressure measurements in the surveillance of vascular accesses. In Gray R (ed): A Multidisciplinary Approach for Hemodialysis Access. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, Chapter 21, pp. 137-150.
15. Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993, 21:457-471.
16. Beathard G. Gianturco self-expanding stents in the treatment of stenosis in dialysis access grafts. Kidney Int 1993, 43:872-877.
17. Valji K, Bookstein JJ, Roberts AC et al. Pharmacomechanical thrombolysis and angioplasty in the management of clotted graft. Early and late clinical results. Radiology 1991, 178:243-247.
18. Trerotola SO, Lund GB, Scheel PJ et al. Thrombosed dialysis access grafts: percutaneous mechanical declotting without urokinase. Radiology 1994, 191:721-726.
19. Uldall R. Hemodialysis access, Part A: Temporary. In Replacement of Renal Function by Dialysis, 4th Edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer Academic Publishers, 1996:277-293.
20. Hernández D, Díaz F, Rufino M et al. Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. J Am Soc Nephrol 1998, 9:1507-1510.
21. De Vries PJ, Kouw PM, van der Meer N et al. Non-invasive monitoring of blood volume during hemodialysis: its relation with post-dialytic dry weight. Kidney Int 1993, 44:851-854.
22. Hampl H, Paeprer H, Unger V et al. Hemodynamics during hemodialysis, sequential ultrafiltration and hemofiltration. J Dial 1979, 3:51-71.
23. Pagel MD, Ahmad S, Vizzo JE, Scribner BH: Acetate and bicarbonate fluctuations and acetate intolerance during dialysis. Kid Int 1982, 21:513-518.
24. Sadowski RH, Allred EN, Jabs K. Sodium modeling ameliorates intradialytic and interdialytic symptoms in young hemodialysis patients. Am Soc Nephrol 1993, 4:1192-1198.
25. Maggiore Q, Pizzarelli F, Zoccali C et al. Influence of blood temperature on vascular stability during hemodialysis and isolated ultrafiltration. Int J Artif Organs 1985, 8:175-178.
26. Chazan J. Sudden death in patients with chronic renal failure on hemodialysis. Dial Transplant 1987, 16:447.
27. Amerling R, Cu GA, Dubrow A et al. Complications during hemodialysis. In Clinical Dialysis, 3rd Edition. Edited by AR Nissenson, RN Fine, and DE Gentile. Norwalk: Appleton & Lange, 1995;235-267.
28. Golper TA, Wolfson M, Ahmad S et al. Multicenter trial of l-carnitine in maintenance hemodialysis patients, I, Carnitine concentrations and lipid effects. Kidney Int 1990, 38:904-911.
29. Ahmad S, Roberston HT, Golper TA et al. Multicenter trial of l-carnitine in maintenance of hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990, 38:912-918.
30. Khoss AE, Steger H, Legenstein E et al. L-carnitine therapy and myocardial function in children treated with chronic hemodialysis. Wien Klin Wochenschr 1989, 101:17-20.
31. Garnaas KR, Windebank AJ, Blexrud MD et al. Ultrastructure changes produced in dorsal root ganglia in vitro by exposure to ethylene oxide from hemodialysis. J Neuropathol Exp Neurol 1991, 50:256-262.
32. Schulman G, Hakim R, Arias R et al. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. Am Soc Nephrol 1993, 3:1563-1569.
33. Pegues DA, Beck-Sague, Woolen SW et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992, 42:1232-1237.
34. Rigby AJ, Scribner BH, Ahmad S. Sodium, not fluid, controls interdialytic weight gain. Nephrol News & Issues 2000, 14(9):21-22.
35. Babb AL, Popovich RP, Christopher TG et al. The genesis of square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 1971, 17:81-91.
36. Babb AL, Strand MD, Uvelli DA et al. Quantitive description of dialysis treatment: a dialysis index. Kidney Int 1975, 2:23-29.
37. Scribner BH. Discussion. Trans Am Soc Artif Intern Organs 1965, 11:29.4;
38. Johnson WJ, Hagge WW, Wagoner RD et al. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972, 47:21-29.
39. Milutinovic J, Babb AL, Eschbach JW et al. Uremic neuropathy: evidence of middle molecule toxicity. Artif Organs 1978, 2:45-51.
40. Ahmad S, Babb AL, Milutinovic J et al. Effect of residual renal function on minimum dialysis requirements. Proc Eur Dial Transplant Assoc 1979, 16:107-114.
41. Teschan PE, Ginn HE, Bourne, JR et al. Neurobehavioral probes for adequacy of dialysis. Trans Am Soc Artif Intern Organs 1977, 23:556-559.
42. Gotch FA. A quantitative evaluation of small molecule and middle molecule toxicity in therapy of uremia. Dial Transplant 1980, 9:183-186.
43. Gotch F, Sargent J. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985, 28:526-534.
44. Garred LJ, Canaud BC, McCready WG. Optimal hemodialysis-The role of quantification. Sem Dial 1994, 7:236-240.
45. Owen WF Jr, Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentrations as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993, 329:1001-1006.
46. Daugirdas JT. Simplified equations for monitoring Kt/V, PCRn, eKt/V and ePRCn. Adv Ren Replace Ther 1995, 2:295-304.
47. Daugirdas JT. Estimation of equilibrated Kt/V using unequilibrated postdialysis BUN. Sem Dial 1995, 8:23-26.
48. Daugirdas JT, Depner TA. A nomogram approach to hemodialysis urea modeling. Am J Kidney Dis 1994, 23:33-40.
49. Depner T, Daugirdas J. Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nepherol 1996 7:780-785.
50. Charra B, Calemard E, Cuche M, et al. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephrol 1983, 33:96-102.
51. Ahmad S. A simple method to monitor the dose of hemodialysis. ASAIO J 1997, 43:298-302.
52. Kramer P, Wigger W, Reiger J, et al. Arteriovenous hemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin Wochenschr. 1977;55:1121-1122.
53. Tominaga GT, Ingegno M, Cerldi C, Waxman K. Vascular complications of continuous arteriovenous hemofiltration in trauma patients. J Trauma. 1993;35:285.
54. Bellomo R, Parkin G, Love J, Boyce, N. A prospective comparative study of continuous arteriovenous hemodiafiltration and continuous venovenous hemodiafiltration in critically ill patients. Am J Kidney Dis. 1993;21:400.
55. Kaplan AA. Continuous arteriovenous hemofiltration and related therapies. In: Replacement of Renal Function by Dialysis. 4th edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer, 1993, pp. 390-418.
56. Tam, PY-W, Huraib S, Mahan B, et al. Slow continuous hemodialysis for the management of acute renal failure in an intensive care unit. Clin Nephrol. 1988;30:79.
57. CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections. MMWR August 9, 2002/51(RR10), pp. 1-26.
58. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis, 4th edition. Philadelphia, PA: Lippincott William & Wilkins, 2007.
59. Shrader J, Scheler F. Coagulation disorders in acute renal failure and anticoagulation during CAVH with standard heparin and LMW heparin. In: Continuous Arteriovenous Hemofiltration. Edited by HG Sieberth and H Mann. Basel: Karger, 1985, pp. 25-55.
60. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials. J Am Soc Nephrol. 2004;15:3192-3206.
61. Reeves JH, Cumming AR, Gallagher L, et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtrations. Crit Care Med. 1999;27:2224-2228.
62. Ahmad S, Yeo KT, Jensen WM, et al. Citrate anticoagulation during in vivo simulation of slow hemofiltration. Blood Purif. 1990;8:177-182.
63. Mehta RL, McDonald BR, Aguilar MM, et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976-981.
64. Swartz R, et al. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol. 2004;61:134-143.
65. Tu A, et al. Heparin Free Slow Low Efficiency Dialysis (SLED) Using Citrate Dialysate Is Safe and Effective. Poster presented at the 12th International Conference on Continuous Renal Replacement Therapies (CRRT) March 7-10, 2007, San Diego, CA.
66. Tu A, et al. Citrate Dialysate in SLED Is Safe and Effective in the Presence of Severe Liver Dysfunction. Poster presented at the European Renal Association and European Dialysis and Transplant Association Congress, Barcelona, Spain, June 2007.
67. Winrow RM, Tu A, Ahmad S. Intra-operative dialysis during liver transplantation for fulminant liver failure using citrate dialysate. European Renal Association-European Dialysis and Transplant Association Annual Congress. Stockholm, Sweden. May 10-13, 2008.
68. Zobel G, Trop M, Muntean W, et al. Anticoagulation for continuous arteriovenous hemofiltration in children. Blood Purif. 1988;6:90-95.
69. Fiaccadori E, Maggiore U, Rotelli C, Minari M, Melfa L, Cappe G, Cabassi A. Continuous hemofiltration in acute renal failure with prostacyclin as the sole anti-hemostatic agent. Intensive Care Med. 2002;28:586-593.
70. Balik M, Waldauf P, Plasil P, Pachl J. Prostacyclin versus citrate in continuous hemofiltration: an observational study in patients with high risk of bleeding. Blood Purif. 2005;232:325-329.
71. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron. 1994;66:431-437.
72. Kozek-Langenecke SA, Spiss CK, Gamsjager T, Domenig C, Zimpfer M. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous hemofiltrations: a randomized controlled trial. Wien Klin Wochenschr. 2002;114:96-101.
73. Davenport A, Will EJ, Davison AM. The effect of prostacyclin on intracranial pressure in patients with acute hepatic and renal failure. Clin Nephrol. 1991;35:151-157.
74. Davenport A, Will EJ, Davison AM. Adverse effects on cerebral perfusion of prostacyclin administration directly into patients with fulminant hepatic failure and acute renal failure. Nephron. 1991;59:449-454.
75. Davenport A, Will EJ, Davison AM. Adverse effects of prostacyclin administered directly into patients with combined renal and respiratory failure prior to dialysis. Intensive Care Med. 1990;16:431-435.
76. Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005;39:1601-1605.
77. Hein OV, Heymann C, Morgera S, Konertz W, Ziemer S, Spies C. Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure. Artif Organs. 2005;29:507-510.
78. Flanigan MJ, Von Brecht J, Freeman RM, Lin VS. Reducing the hemorrhagic complications of hemodialysis: A controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis. 1987;9:147-153.
79. Ohtake Y, Hirasawa H, Sugai T, et al. A study on anticoagulants in continuous hemofiltration. Jpn J Artif Organs. 1990;19:744.
80. Inagaki O, Nishian Y, Iwaki R, Nakagawa K, Takamitsu Y, Fujita Y. Adsorption of nafamostat mesylate by hemodialysis membranes. Artif Organs. 1992;16:553-558.
81. Miyahara K, Maeda M, Sakurai H, Nakayama M, Murayama H, Hasegawa H. Cardiovascular surgery in patients on chronic dialysis: effect of intraoperative hemodialysis. Inter Cardiovas Thorac Surg 2004;3:148-152.
82. Fukumoto A, Yamagishi M, Kiyoshi D, Ogawa M, Inoue T, Hashimoto S, Yaku H. Hemodiafiltration during cardiac surgery in patients on chronic hemodialysis. J Card Surg. 2006;21:553-558.
83. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: a prospective randomized trail. Lancet. 2000;356(9223):26-30.
84. Saudan P, Niederberger M, De Seigneux S, Ramand J, Pugin J, Perneger T, Martin PY. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006;70(7):1312-7.
85. Palevsky PM, O'Connor T, Zhang JH, Star RA, Smith MW. Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clin Trials. 2005;2(5):423-35.
86. Bellomo R. Do we know the optimal dose for renal replacement therapy in the intensive care unit? Kidney Int. 2006;70(7):1202-1204.
87. Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: A meta-analysis. Crit Care Med. 2008;36(2):610-617.
88. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. for the Alberta Kidney Disease Network. Renal replacement therapy in patients with acute renal failure: A systematic review. JAMA. 2008;299(7):793-805.
89. Ganter G. Uber die Beseitigung giftiger Stoffe aus dem Blute durch Dialyse. Muench Med Wochenschr 1923, 70:1478-1485.
90. Boen ST. Kinetics of peritoneal dialysis. Medicine 1961, 40:243.
91. Tenckhoff H, Schechter H. A bacteriologically safe peritoneal access device. Trans Am Soc Artif Intern Organs 1968, 14:181-187.
92. Popovich RP, Moncrief JW, Decherd JF et al. The definition of a novel portable-wearable equilibrium peritoneal technique [Abstract]. Am Soc Artif Intern Org 1976, 22:64.
93. Oreopoulos DG, Robson M, Izatt S, et al. A simple and safe technique for continuous ambulatory peritoneal dialysis (CAPD). Trans Am Soc Artif Intern Organs 1978, 24:484-489.
94. Scribner BH. A current perspective on the role of intermittent versus continuous ambulatory peritoneal disease in the treatment of chronic renal failure. In Pro Northeastern Meeting, Renal Physicians Association Symposium on Peritoneal Dialysis 1979;3:76-81.
95. Diaz-Buxo JA, Farmer CD, Walker PJ et al. Continuous cyclic peritoneal dialysis - A preliminary report. Artif Organs 1981, 5:157-161.
96. Twardowski ZJ. Physiology of Peritoneal Dialysis. In Clinical Dialysis, 3rd edition. edited by AR Nissensson, RN Fine, and DE Gentile. Norwalk: Appleton and Lange, 1995:322-342.
97. Nolph KD, Miller F, Rubin J et al. New directions in peritoneal dialysis concepts and applications. Kidney Int 1980, 18(Suppl 10):111-116.
98. Mactier RA, Khanna R, Twardowski ZJ et al. Contribution of lymphatic absorption to loss of ultrafiltration and solute clearance in continuous ambulatory peritoneal dialysis. J Clin Invest 1987, 80:1311-1316.
99. Rippe B, Zakaria ER. Lymphatic versus nonlymphatic fluid absorption from the peritoneal cavity as related to the peritoneal ultrafiltration capacity and sieving properties. Blood Purif 1992, 10:189-202.
100. Tenckhoff H. Peritoneal Dialysis Manual. Washington, DC: University of Washington; 1974.
101. Twardowski ZJ, Khanna R, Nolph KD. Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 1986, 42:93-101.
102. Feriani M, Ronco C, La Greca G. Solutions for peritoneal dialysis. In Replacement of renal function by dialysis. 4th Edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer Academic Publications, 1996:520-546.
103. Diaz-Buxo JA. Clinical use of peritoneal dialysis. In Clinical Dialysis, 3rd edition. Edited by AR Nissenson, RN Fine and DE Gentile. Norwalk: Appleton and Lange, 1995:376-425.
104. Jones MR, Martis L, Algrim CE et al. Amino acids solutions for CAPD: rationale and clinical experience. Miner Electrolyte Metab 1992, 18:309-315.
105. Anonymous. NKF-DOQI Clinical practice guidelines for peritoneal dialysis adequacy. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997, 30(Suppl 2):S67-S136.
106. Boen ST, Haagsma-Schouten W A G et al. Long-term peritoneal dialysis and a dialysis index. Dial Transplant 1978, 7:377.
107. Diaz-Buxo JA. Chronic peritoneal dialysis prescription. In Handbook of Dialysis 2nd Edition. Edited by JT Daugirdas and TS Ing. Philadelphia: Lippincott-Raven, 1993, pp. 310-327.
108. Twardowski ZJ. Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 1989, 7:95-108.
109. Verger C, Larpent L, Dumontet M. Prognostic value of peritoneal equilibration curves in CAPD patients. In Frontiers in Peritoneal Dialysis. Edited by JF Maher and JF Winchester. New York: Rich and Associates, 1986, pp. 88-93.
110. Diaz-Buxo JA. Clinical use of peritoneal dialysis. In Clinical Dialysis 2nd Edition. Edited by AR Nissenson, RN Fine, and DE Gentile. Norwalk: Appleton and Lange, 1990, vol 13, pp. 256-300.
111. Twardowski ZJ et al. Peritoneal equilibration test. Perit Dial Bull 1987, 7:138-140.
112. Jensen RA, Nolph KD, Moore HL et al. Weight limitations for adequate therapy using commonly performed CAPD and IPD regimens. Seminars Dial 1994, 7:61.
113. Goodman CE, Husserl FE. Etiology, prevention and treatment of back pain in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Bull 1981, 1:119-122.
114. Anonymous. Catheter related factors and peritonitis risks in CAPD patients. Am J Kidney Dis 1992, 20(Suppl 2):48-54.
115. Gokal R. Peritoneal infections, hernias and related complications. In Replacement of Renal Function by Dialysis. 4th Edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer, 1996:657-688.
116. Johnson R, Ramsey PG, Gallagher N et al. Fungal peritoneal infections in patients on chronic peritoneal dialysis. Am J Nephrol 1985, 5:169-175.
117. Keane WF, Vas SI. Peritonitis. In The Textbook of Peritoneal Dialysis. Edited by R Gokal and KD Nolph. Dordrecht: Kluwer, 1994:473-503.
118. Bargman JM. Noninfectious complications of peritoneal dialysis. In The Textbook of Peritoneal Dialysis. Edited by R Gokal and KD Nolph. Dordrecht: Kluwer, 1994:555-591.
119. Fouque D, Kopple JD. Malnutrition and dialysis. In Replacement of Renal Function by Dialysis. 4th Edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer, 1996, pp. 1271-1290.
120. Jacob V, Le Carpentier JE, Salazano S et al. IGF-1, a marker of undernutrition in hemodialysis patients. Am J Clin Nutr 1990 52:39-44.
121. Bergstrom J. Nutrition and adequacy of dialysis in hemodialysis patients. Kidney Int Suppl 1993, 41:S261-S267.
122. Eknoyan G, Beck GJ, Breyer JA et al. Design and preliminary results of the mortality and morbidity of hemodialysis (MMHD) pilot study [Abstract]. J Am Soc Nephrol 1994, 5:513.
123. Lowrie EG, Lew LN. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990, 5:458-482.
124. Acchiardo SR, Moore LW, Latour PA. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int 1983, 24:199-203.
125. Owen WF, Lew NL, Liu Y et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993, 329:1001-1006.
126. Collins AJ, Ma JZ, Umen A et al. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994, 23:272-282.
127. Charra B. Personal communication.
128. Teehan BP, Schleifer CR, Brown JM et al. Urea kinetic analysis and clinical outcome on CAPD. A five year longitudinal study. Adv Perit Dial 1990, 6:181-185.
129. Blake PG, Flowerdew G, Blake RM et al. Serum albumin in patients on continuous ambulatory peritoneal dialysis-predictors and correlations with outcomes. J Am Soc Nephrol 1993, 3:1501-1507.
130. Kashaviah P, Curchill DN, Thorpe K et al. Impact of nutrition on CAPD mortality. J Am Soc Nephrol 1994, 5:A494.
131. Donahue PR, Ahmad S. Dialyzer permeability alteration by reuse [Abstract]. J Am Soc Nephrol 1992, 3:363.
132. Enia G, Sicuso C, Alati G et al. Subjective global assessment of nutrition in dialysis patients. Nephrol Dial Transplant 1993, 8:1094-1098.
133. Churchill DN, Taylor DW, Keshaviah PR. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 1996, 7:198-203.
134. Borah MF, Schoenfeld PY, Gotch FA et al. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978, 14:491-500.
135. Ahmad S. Carnitine, kidney and renal dialysis. In L-carnitine and its role in medicine. From function to therapy. Edited by R Ferrari, S Dimauro and G Sherwoods. California: Academic Press, 1991, pp. 381-400.
136. Dasgupta A, Kenny MA, Ahmad S. Abnormal fatty acid profile in chronic hemodialysis patients: possible deficiency of essential fatty acids. Clinical Physiol Biochem 1990, 8:238-243.
137. Lacour B, Roullet JB, Drueke T. Les perturbations du metabolisme lipidique dans l'insuffisance renale chronique. Nephrologie 1983, 4:75-81.
138. Ahmad S, Dasgupta A, Kenny MA. Fatty acid abnormalities in hemodialysis patients: effect of L-carnitine administration. Kidney Int Suppl 1989, 36:S243-S246.
139. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end stage renal disease. Kidney Int Suppl 1996, 57:S11-S17.
140. Yeun JY. The role of homocysteine in end stage renal disease. Semin Dial 1998, 11:95.
141. Bostom AG, Culleton B. Hyperhomocysteinemia in chronic renal disease: potential relevance to arteriosclerosis. Semin Dial 1999, 12:103-111.
142. Chertow GM, Ling J, Lew NL et al. The association of intradialytic parenteral nutrition administration with survival in hemodialysis patients. Am J Kidney Dis 1994, 24:912-920.
143. Capelli JP, Kushner H, Camiscioli TC et al. Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 1994, 23:808-816.
144. Williams AJ, Dittmer ID, McArley A et al. High bicarbonate dialysate in haemodialysis patients: effects on acidosis and nutritional status. Nephrol Dial Transplant 1997, 12:2633-2637.
145. Guest SS, Berenji MS, Kirsch CM et al. Functional consequences of correction of metabolic acidosis in hemodialysis patients. J Am Soc Nephrol 1997, 8:236A.
146. Ahmad S, Pagel M, Vizzo J et al. Effect of the normalization of acid-base balance on post dialysis plasma bicarbonate. Trans Am Soc Artif Intern Organs 1980, 26:318-321.
147. Erturk S, Ertug AE, Ates K et al. Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in haemodialysis patients. Nephrol Dial Transplant 1996, 11:2050-2054.
148. Charra B, Calemard E, Cuche M et al. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephrol 1983, 33:96-102.
149. Charra B, Laurent G, Chazot C et al. Hemodialysis trends in time, 1989 to 1998, independent of dose and outcome. Am J Kidney Dis 1998, 32(Suppl 4):S63.
150. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 115(4):291-297, 2003.
151. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
152. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end stage renal disease in men. N Engl J Med 1996, 334:13-18.
153. Haire HM, Sherrard DJ, Scardapne D et al. Smoking, hypertension and mortality in a maintenance dialysis population. Cardiovasc Med 1978, 3:1163-1166.
154. Harnet JD, Parfrey PS, Griffiths SM et al. Left ventricular hypertrophy in end-stage renal disease. Nephron 1988, 48:107-115.
155. Buonchristiani U, Fagugli RM, Pinciaroli MR et al. Reversal of left ventricular hypertrophy in uremic patients by treatment of daily hemodialysis (dhd). Contrib Nephrol 1996, 119:152-156.
156. London G, Marchais S, Guerin AP. Blood pressure control in chronic hemodialysis patients. In Replacement of Renal Function by Dialysis, 4th Edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer, 1996:966-990.
157. Raine A E G, Bedford L, Simpson AW et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993, 43:700-705.
158. Solomon R, Dubey A. Diltiazem enhances potassium disposal in subjects with end stage renal disease. Am J Kidney Dis 1992, 19:420-422.
159. Marchais SJ, Boussac I, Guerin AP et al. Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. J Cardiovasc Pharmacol 1991, 18(Suppl 1):S74-S78.
160. Friedman EA (ed.). Death on hemodialysis: preventable or inevitable? Dordrecht: Kluwer; 1994.
161. Bright R. Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine. Guys Hosp Rep 1836, 1:338.
162. Naets JP, Garcia JF, Toussaint C et al. Radioimmunoassay of erythropoietin in chronic uremia or anephric patients. Scand J Haematol 1986, 37:390-394.
163. London G, Marchais S, Guerin AP. Blood pressure control in chronic hemodialysis patients. In Replacement of Renal Function by Dialysis, 4th Edition. Edited by C Jacobs, CM Kjellstrand, KM Koch and JF Winchester. Dordrecht: Kluwer, 1996:966-990.
164. Charra B. Personal communication.
165. Wallner SF, Vautrin RM. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 1981, 97:170.
166. Moritz JL, Jensen WM, Ahmad S. Prospective study in patients on low dose of recombinant erythropoietin (Epo): hematocrit (HCT), blood pressure and hemodynamic responses. J Am Soc Nephrol 1990, 1:403.
167. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997, 29:319.
168. Gupta A, Amin NB, Besars A et al. Dialysate iron therapy: infusion of ferric pyrophosphate via the dialysate in maintenance hemodialysis (HD) patients. J Am Soc Nephrol 1998, 9:251A.
169. Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995, 26:757.
170. Labonia WD, Morelli OH, Gimenez MI et al. Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int 1987, 32:754-759.
171. Megri K, Trombert JC, Zannier A. Role of L-carnitine deficiency in persistent anemia of maintenance hemodialysis (MHD) patients treated by erythropoietin (EPO) [Abstract]. Societe Francaise De Nephrologie Toulouse. 1997;153.
172. Barrillon D, Cassuto-Viguier E, Iordache A et al. Role of L-carnitine deficiency in persistent anemia of maintenance hemodialysis (MHD) patients treated by erythropoietin (EPO) [Abstract]. Societe Francaise De Nephrologie Nantes. 1992;103.
173. Savica V, Bellinghieri G, Mallamace A. Value of carnitine in periodic hemodialysis. Rass Med Interna 1986, 7:293-307.
174. Nilsson-Ehle P, Cederblad G, Fagher B et al. Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest 1985, 45:179-184.
175. Bellingheri G, Savica V, Mallamace A et al. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 1983, 38:523-531.
176. Donatelli M, Terrizzi C, Zummo G et al. Effects of L-carnitine on chronic anemia and erythrocyte adenosine triphosphate concentration in hemodialyzed patients. Curr Ther Res 1987, 41:620-624.
177. Mioli V, Tarchini R, Boggi R. Use of D, L-, and L-carnitine in uraemic patients on intermittent haemodialysis. Int J Clin Pharm Res 1982, 2:143-148.
178. Trovato G, Ginardi V, Di Marco V et al. Long term l-carnitine treatment of chronic anemia of patients with end-stage renal failure. Curr Ther Res 1982, 31:1042.
179. Caruso U, Leone L, Cravotto E et al. Effects of l-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin. Dial Transplant 1998, 27:498.
180. Thompson CH, Irish AB, Kemp GJ et al. The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure. Clin Nephrol 1997, 47:372-378.
181. Albertazzi A, Capelli P, Di-Paolo B et al. Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 1983, 19:302-307.
182. Matsumura M, Hatakeyama S, Koni I et al. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996, 72:574-578.
183. Rose BD, Rennke HG. Signs and symptoms of chronic renal failure. In Renal Pathophysiology. Edited by BD Rose and HG Rennke. Baltimore: Williams & Wilkins, 1994:276-300.
184. Lucas PA, Brown, RC Woodhead JS et al. 1, 25-dihydroxycholecalciferol and parathyroid hormone in advanced renal failure: effects of simultaneous protein and phosphate restriction. Clin Nephrol 1986, 25:7-10.
185. Tessitore N, Venturi A, Adami S et al. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Miner Electrolyte Metab 1987, 13:38-44.
186. Bricker NS. On the pathogenesis of the uremic state. An exposition of the 'trade-off hypothesis'. N Engl J Med 1972, 286:1093-1099
187. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end stage renal failure, An evolving disorder. Kidney Int 1993, 43:436-442.
188. Barata JD, D'Haese PC, Pires C et al. Low dose (5 mg/kg) desferrioxamine treatment in acutely intoxicated hemodialysis patients using two drug administration schedule. Nephrol Dial Transplant 1996, 11:125-132.
189. Couttenye MM, D'Haese PC, Van-Hool VO et al. Low serum alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant 1996, 11:1065-1072.
190. Jadoul M, Garbar C, Noel H et al. Histological prevalence of beta-2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 1997, 51:1928-1932.
191. Koda Y, Nishi SI, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997, 52:1096-1101.
192. Gipstein RM, Coburn JW, Adams DA et al. Calciphylaxis in man. Arch Intern Med 1976, 136:1273-80.
193. Bleyer AJ, Choi M, Igwemezie B et al. A case control study of proximal calciphylaxis. Am J Kidney Dis 1998, 32:376-383.
194. Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently associated with chronic renal failure. Am J Kidney Dis 1997, 30:809-813.
195. Block GA, Hubert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1999, 31:607-617.
196. Couttenye MM, D'Haese PC, Van-Hool VO et al. Low serum alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant 1996, 11:1065-1072.
197. Pei Y, Hercz G, Greenwood C et al. Non-invasive prediction of aluminum bone disease in hemodialysis patients. Kidney Int 1992, 41:1374-1382.
198. Antonsen JE, Hercz G, Pei Y et al. Random plasma aluminum is not useful in screening for aluminum bone disease. J Am Soc Nephrol 1997, 8:548A.
199. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994, 4:1631-1642.
200. Wang M, Hercz G, Sherrard DJ. Relationship between intact parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995, 5:836-844.
201. Dusso AS, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis 1998, 32(Suppl 2):S13-S24.
202. Quarles LD, Yohay DA, Carrol BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994, 45:1710-21.
203. Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (Paricalcitriol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998, 9:1427-1432.
204. Slatopolsky EA, Burke SK, Dillon MS. Renegal, a nonabsorbed calcium-and aluminum free phosphate binder, lowers serum phosphorus and parathyroid hormone. The Renegal Study Group. Kidney Int 1999, 55:299-307.
205. Mucsi I, Hercz G, Uldall R et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998, 53:1399-1404.
206. Ahmad S, Vizzo JE, Scribner BH. Reduction in aluminum load after one year of hemodiafiltration. ASAIO Trans 1986;32:370-373.
207. Stehman-Breen C, Muihead N, Thorning D et al. Secondary hyperparathyroidism complicated by parathyromatosis. Am J Kidney Dis 1996, 28:502-507.
208. Alem AM, Sherrard DJ. Renal osteodystrophy. In Principles and practice of dialysis, 2nd Edition. Edited by WL Henrich. Baltimore: William & Wilkins, 1998, pp. 328-340.
209. Haddad LM, Shannon MW, Winchester JF eds. Clinical management of poisoning and drug overdose, 3rd edition Philadelphia: WB Saunders, 1998.
210. Teschan PE, Ahmad S, Hull AR et al. Panel conference. Daily dialysis-applications and problems. Trans Am Soc Artif Intern Organs 1980, 26:600-602.